CLL remains incurable with the standard therapy. Allogeneic hematopoietic stem cell transplant may be curative. We examined 50 patients with advanced CLL who underwent allogeneic HCT at the University of Michigan between 1996 and 2006. Twenty-one patients received reduced-intensity conditioning (RIC) and twentynine patients received full-intensity conditioning (FIC) consisting of CY, etoposide and BCNU (n ¼ 20) or BU and CY (n ¼ 9). RIC recipients were older than FIC recipients (median age 54 vs 51, P ¼ 0.009). There were no statistically significant differences between groups in terms of the number of earlier therapies or patients with adverse cytogenetics. There were more unrelated donors in the RIC group 62% than in the FIC group 31% (P ¼ 0.030). Despite their older age and greater use of URD, the 5-year overall survival (OS) rate was 63% in the RIC group as compared with 18% in the FIC group (P ¼ 0.006). The primary cause of inferior survival in the FIC recipients was TRM, which was twice as high at day 100 for the FIC group 27% compared with the RIC group 14% (P ¼ 0.005). The relapse rate was 15% regardless with the majority of relapses occurring after day 100. These results suggest a favorable outcome for advanced CLL who undergo a RIC regimen compared with FIC.
Introduction
Even with the recent advances in therapeutic options such as rituximab or alemtuzumab, CLL remains incurable with conventional therapies. [1] [2] [3] The prognosis of CLL is particularly poor whether there are adverse biological risk factors such as unfavorable cytogenetics, expression of the ZAP-70 gene product, or unmutated status of the variable region of the Ig heavy-chain gene. 3, 4 Autologous HCT may extend survival, but is unlikely to be curative. [4] [5] [6] [7] [8] [9] [10] Compelling evidence for a GVL effect in CLL rests on the observation that, even in patients with advanced diseases, long-term remissions can be achieved after allogeneic hematopoietic SCT (HCT). [11] [12] [13] A major drawback to these studies, which employed conventional full-intensity conditioning (FIC), was high TRM rates (up to 40%), which offset the high complete response rates. 5, 7, 14, 15 Recently, reduced-intensity conditioning (RIC) HCT has been used to reduce the high rates of TRM associated with FIC. [16] [17] [18] [19] A retrospective analysis comparing RIC with FIC showed a decreased rate of upfront TRM, but an increased rate of relapse in RIC patients, resulting in equivalent 5-year overall survival (OS). 19, 20 We analyzed the outcomes of patients with CLL who underwent an allogeneic HCT at the University of Michigan over the last 10-year period in relation to the intensity of conditioning using either FIC or RIC.
Patients and methods
Fifty patients with CLL underwent allogeneic HCT at the University of Michigan between July 1995 and August 2005. Patient characteristics are shown in Table 1 . To undergo transplantation with a FIC regimen, patients had to be o62 years old and had to show adequate organ function (serum creatinine p2.0 g per 100 ml, bilirubin, aspartate aminotransferase and alanine aminotransferase less than five times the upper limit of normal, cardiac ejection fraction X50%, carbon monoxide diffusion capacity of the lung X50% predicted), and had to have a Karnofsky performance status of equal or above X70%. To undergo transplant with a RIC regimen patients had to be o70 years old, and had to show adequate organ function for RIC (serum creatinine o2.0 g per 100 ml, bilirubin, aspartate aminotransferase and alanine aminotransferase less than or equal to five times the upper limit of normal, cardiac ejection fraction X40%, carbon monoxide diffusion capacity of the lung X40% predicted) and had to have a Karnofsky performance status of equal or above X60%. The decision to pursue FIC rather than RIC was based on the discretion of the treating physician and based on the criteria listed above. Two patients received donor lymphocyte infusion, one patient in each group. The majority of FIC transplants were performed between 1996 and 2003, whereas the majority of the RIC were performed between 2003 and 2006.
Donors
All donor-recipient pairs had HLA typing results compared by mid-resolution techniques in class I loci and highresolution techniques in class II loci. In the two groups, six HLA mismatches were present. In the FIC group a C mismatch was present, whereas in the RIC group four C mismatches and one A mismatch was present. HLA Filgrastim mobilized PBSCs were used in 48 patients and two patients received BM. 
Conditioning regimens and GVHD prophylaxis

Supportive care
All patients received prophylaxis for pneumocystic carinii pneumonia and varicella zoster virus reactivation. CMV was monitored by a weekly quantitative PCR and preemptive antiviral therapy initiated for positive assay. Acute and chronic GVHD was graded according to consensus criteria. 21 Cytogenetics and prognostic features Metaphase analysis for karyotype was performed on BM aspirates or peripheral blood before HCT, together with FISH (performed according to the standard clinical protocol using commercial probes for D13S319, CEP12 at 12p11.1-q11. 1, ATM at 11q22.3 and P53 at 17p13.1 Vysis, Des Plains, IL, USA) for the most common CLL abnormalities, including trisomy 12, deletion 13q, 17p and 11q. Cytogenetics were classified as favorable (normal or trisomy 12, del 13q), unfavorable (complex, del 11q, del 17p) or inevaluable (no data available).
Secondary to the time period in which the patients were treated, limited data on the mutational status of the Ig heavy-chain gene and the ZAP-70 were available. The mutational status of the Ig heavychain was known for six patients in the FIC group of whom four were unmutated (498% homology to germline), in the RIC eight patients of whom five were unmutated. These factors were not included in the analysis because of the incomplete nature of the data.
Statistical analysis
Differences in categorical variables were calculated by the Chi-square test or Fisher's exact test. Differences in continuous variables were calculated by the Wilcoxon rank-sum test. The prognostic value was evaluated by analyzing OS and disease-free survival (DFS). Survival curves were calculated using the Kaplan-Meier survival analysis and comparison between groups was performed by the log-rank test. TRM was defined as death without disease progression. The cumulative incidence of relapse and TRM were evaluated using Gray's method, considering each other risk as a competing risk. Univariate analyses for DFS were computed from the log-rank test. Variables that achieved statistical significance (Po0.05) in the univariate analyses were subsequently included in multivariate analysis for DFS using the Cox regression model (Tables 2 and 3) .
Results
The patients' characteristics are detailed in Table 1 . The median age of patients was 3 years younger in the patients treated with FIC (median age 51) compared with those treated with RIC (median age 54) (P ¼ 0.009). It is of note that seven of the twenty-one patients treated in the RIC group were X62 years of age. The median time from diagnosis to HCT was similar for patients in both groups (58 months in FIC vs 61 months in RIC, P ¼ 0.66). The majority of patients in both groups were heavily pretreated. FIC patients received a median of four (range 1-6) earlier therapies, and RIC patients received a median of three (range 1-6) therapies. Earlier therapies included fludarabine in 49/50 (98%), alkylating agents in 45/50 (90%), Abbreviations: FIC ¼ full-intensity conditioning; RIC ¼ reduced-intensity conditioning.
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Progressive disease was documented in 20/29 (69%) of patients treated with FIC and 14/21 (66%) of the patients treated with RIC. In the FIC 12% of patients had failed to respond to any therapy (induction failure), whereas 10% in the RIC group had induction failure. At the time of transplant, residual leukemia involving more than 10% in the BM was present in 55% of patients treated with FIC and 24% of patients treated with RIC. All patients in both groups had stage IV disease before transplantation. Highrisk cytogenetic abnormalities were present in 11 patients in the RIC with five patients having del 17p, and of the 20 patients having high-risk cytogenetics eight had del 17p in the FIC. In patients who received RIC, the donor source consisted of matched unrelated donor (URD) in eight patients (38%) including five (23%) with a one-locus mismatch. Comparatively, in the FIC patients, the donor source also consisted of matched URD in eight patients (27%), with one being a one-locus mismatch.
GVHD and survival
The incidence of grades II-IV acute GVHD was 39% in patients treated with RIC and 55% in patients treated with FIC. Extensive chronic GVHD was observed in 38% of patients treated with RIC and 48% of patients treated with FIC. The 100-day TRM was 14% in the RIC group and 27% in the FIC group (P ¼ 0.005). Relapse rates at 2 years were similar, RIC 15% vs 14% in FIC (P ¼ 0.005). The most frequent causes of TRM at 1 year were GVHD (n ¼ 4), veno-occlusive disease (n ¼ 5) and infection-related complications (n ¼ 6). The complications such as venoocclusive disease (VOD) and infection occurred in a large portion of patients undergoing a FIC regimen ( Table 3) . The difference in TRM was translated into significantly improved 5-year survival rate in patients treated with RIC (63%) as compared with patients treated with FIC (18%) (P ¼ 0.005) (Figure 1 ). Univariate analysis was performed to evaluate pre-transplantation characteristics between the two groups that would be predictive of DFS after transplantation. Factors that were assessed included age, type of donor (unrelated vs related), cytogenetics, number of earlier therapies, time from diagnosis to HCT and degree of BM involvement. Of the factors listed above, both the conditioning regimen (RIC vs FIC P ¼ 0.006) and the degree of BM involvement (410% vs o10% P ¼ o0.001) were shown to be significant predictors of DFS (Figure 2) . In multivariate analysis, variables that achieved statistical significance in univariate analysis (Po0.05) were included (Tables 2 and 4 ) and residual leukemia cells 410% were the independent predictors for DFS.
Disease response after transplant After FIC 37% of the patients achieved CR, whereas in the RIC 42% achieved CR with 21% in the FIC and 23% in the RIC achieving PR. Progressive disease occurred in 4% of the FIC and 5% in the RIC group. Reduced intensity stem cell transplant in CLL E Peres et al
Discussion
The conditioning regimen used in patients undergoing HCT with CLL remains controversial. Conventional FIC is restricted to younger and medically fit patients, secondary to concerns of high TRM. 21 As the median age of diagnosis in patients with CLL is 65 years many patients are not eligible for FIC. 21 Recently with the advent of RIC, older patients with CLL are able to undergo HCT. The major concern when using a RIC HCT in patients with CLL is the ability to overcome advanced disease with this conditioning regimen. In our study, we compared the results of using our RIC regimen with the results of using FIC regimens in patients with advanced CLL. A few differences were noted between the group that received RIC and the group that received FIC. First, the patients who received RIC were older with a median age of 54 for RIC patients as compared with 51 for patients treated with FIC. Second, RIC patients received more HLA-mismatched grafts than the FIC group, with URD grafts representing 65% in the RIC patients vs 31% in the FIC group (P ¼ 0.030). In addition, a significantly lower percentage of TRM in the RIC group (14%) than the FIC group (27%) (P ¼ 0.005). Relapse rates at 2 years were 15% in the RIC and 14% in the FIC group and occurred after day 100 in both groups.
Despite all of the negative characteristics in the RIC group OS was superior in this high-risk group.
Our data confirms promising OS compared with FIC in heavily pretreated CLL patients undergoing RIC. Our data are comparable to the reported 5-year OS in the RIC setting in CLL with a similar sample size (Figure 3) . 22 In our RIC group, there were a higher percentage of unrelated donors compared with the FIC group. However, relapse rates at 2 years were similar to the FIC group. Unlike other reports in the literature in which relapse rates are reported to be as high as 40% our relapse rates were similar between the two groups. As reported earlier, the differing degree of BM involvement was a significant predictor of either relapse or survival in both groups of patients. 22 Unlike earlier reports, our relapse rates after RIC and FIC were not statistically different and the majority of relapse occurred beyond day 100 in both treatment groups. Unlike earlier reports in which relapse occurred less than day 100 after transplant. Further studies are needed to elucidate the best conditioning regimen for this group of patients with advanced CLL. In addition, studies are needed to optimize the GVL effect while maintaining low TRM in high-risk patients with CLL. Abbreviations: DFS ¼ disease-free survival; FIC ¼ full-intensity conditioning; RIC ¼ reduced-intensity conditioning.
